biostudies-literatureYin HScience and Technology Commission of Shanghai MunicipalityShanghai Municipal Hospital Development CenterFujian Provincial Department of Science and Technology2https://www.ebi.ac.uk/biostudies/studies/S-EPMC12715071biostudies-literatureUnknown75(1)<h4>Background</h4>Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.<h4>Methods</h4>Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.<h4>Results</h4>Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3 months, median EFSCancer immunology, immunotherapy : CIILong-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.PMC12715071SHDC2020CR40392021D01420ZR1411600Li GTan LLiao XWang JSun YYan XDuan HYang XYin HLiang FFan HWang PChen YYao GfalseLong-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.<h4>Background</h4>Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.<h4>Methods</h4>Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.<h4>Results</h4>Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3 months, median EFS2025-01-01T00:00:00Z2025 Dec2026-06-06T04:59:38.612Z2026-05-26T03:12:14.53ZS-EPMC127150714141074110.1007/s00262-025-04240-8